Skip to main content

Bachem builds its largest production building

Bachem Bubendorf
| News

Bachem builds its largest production building


Bachem has laid the foundation stone for its largest production building to date. The company specializing in the manufacture of peptides and oligonucleotides will initially create up to 150 new skilled jobs with this. This will strengthen the position of Bubendorf, located in the Basel Area, as a center of excellence.

Bachem Bubendorf
Bachem is specializing in the manufacture of peptides and oligonucleotides (img: Bachem)

Bachem has started construction of the world’s most high-tech production building for peptides and oligonucleotides at its location in Bubendorf in the canton of Basel-Landschaft. The foundation stone was laid on Thursday. According to a press release, the building should expand the production capacities for these complex molecules by 2024 at the latest. These substances are used in medicinal products used to treat various diseases.

In a first phase, up to 150 positions, most of which will be highly skilled, are to be created there. The listed company has invested over 150 million Swiss francs and created 400 new jobs at its two sites in Bubendorf and Vionnaz (in the canton of Valais) over the past five years. The new production building will now strengthen the Bubendorf site’s position as a “leading center of excellence for the manufacture of complex pharmaceutical active ingredients” according to the press release. Additionally, it represents a clear commitment to Switzerland and Basel Area as a location.

Since global demand for these molecules is constantly increasing, Bachem is already looking for a third production site in Switzerland. The land reserves at the Bubendorf site will be exhausted in the medium term.

The company celebrated its 50th anniversary this year. CEO Thomas Meier is delighted that the foundation stone was laid on Swiss National Future Day, which is a day for young people to learn about working in a company. Meier adds: “Our success is founded on our ability to invest into our company efficiently and with foresight, but also on the ability to excite new generations for the impact chemistry and the natural sciences can have.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.